Get the Stockscreener App
2.45
6.99%
0.16
I Mab Adr stock is traded at $2.45, with a volume of 1.67M.
It is up +6.99% in the last 24 hours and up +174.94% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$2.29
Open:
$2.5
24h Volume:
1.67M
Relative Volume:
4.64
Market Cap:
$106.98M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.9869
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+87.02%
1M Performance:
+174.94%
6M Performance:
+140.20%
1Y Performance:
+31.02%
1-Day Range:
$2.31
$2.70
1-Week Range:
$1.20
$2.70
52-Week Range:
$0.595
$2.70
I Mab Adr Stock (IMAB) Company Profile
Compare IMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
2.45 | 106.98M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance
Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance
I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa
I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com
Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - TipRanks
I-Mab names Sean Fu as new CEO - Investing.com
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Markets Brief: Stocks Fall for the First Time in a Month, More Retail Earnings Ahead - Morningstar
Sabah does not deserve this, MAB! - Daily Express Malaysia
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database - Frontiers
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):